Azalea Vision Secures €15M in Series A Funding for Ocular Health Technology
Azalea Vision, a leading ocular health company based in Ghent, Belgium, has successfully closed a Series A funding round, securing a total of €15 million, including a €9 million extension.
This funding round was backed by SPRIM Global Investments and Afrimobility, demonstrating strong support for Azalea Vision’s innovative ocular technology platform.
The company plans to utilize this investment to advance its First-in-human (FIH) pilot clinical trial, a crucial step in validating the safety and efficacy of its medically intelligent ocular technology.
Headed by CEO Enrique Vega, Azalea Vision specializes in providing solutions for complex vision conditions, remote diagnostics, and targeted ocular therapies. Their cutting-edge smart lens platform is designed to sense, adapt, and interact in real-time, offering a unique approach to ocular health.
Established in 2021 as a spin-off from imec and Ghent University, Azalea Vision has also announced the appointment of Robert J. Dempsey as Chairman of the Board. Dempsey’s extensive experience in the ophthalmic sector will be instrumental in driving strategic growth in both the European and U.S. markets.
Enrique Vega expressed his enthusiasm about the recent developments, stating, “Additional funding in this round from SPRIM Global Investments and Afrimobility, along with a strategic investor who remains undisclosed, further emphasizes the confidence in our platform. The appointment of Robert J. Dempsey, a highly regarded leader in the ophthalmic space, brings deep domain expertise and strong industry relationships to guide our leadership team as we move forward into our next stage of growth.”
FinSMEs
29/04/2025
